MedicalResearch.com Interview with: Emma Guttman-Yassky, M.D., PhD, Lead investigator of this study Waldman Professor and System Chair Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai, NY   MedicalResearch.com: What is the background for this study? Response: The idea to test how spacing out treatment or even stopping it affects treatment responses once patients are well controlled. Lebrikizumab it is a potent biologic agent with a relatively long-lasting effect. (more…)